Characteristics of patients and infused drug products
| Pt ID . | Sex . | Age (y) . | Cytogenetic anomalies . | Disease phase at infusion . | Donor and HLA matching . | CAR-T product . | CAR+ T cells (×106 cells per kg) . | CAR− T cells (×106 cells per kg) . | Disease status at LD (%) . | Response at d +28 . | Site of relapse . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Allo-CD19 CAR001 | F | 17 | iAmp21 | Second relapse, very early after HSCT | MUD 10/10 | CD19-CAR–Retro_ALLO | 3.0 | 4.24 | BM (0.3) | CR (MRD–) | CNS (CD19–) |
| Allo-CD19 CAR002 | M | 21 | MEF2D/BCL9 | First refractory relapse | MFD | CD19-CAR–Retro_ALLO | 3.0 (before HSCT) | 3.65 | BM (12) + bone (>10 spots) + liver | BM: CR (MRD–); liver: CR; bone: 3 spots | n.a. |
| Allo-CD19 CAR003 | M | 29 | KMT2A | Fifth relapse | MFD | CD19-CAR–Retro_ALLO | 3.0 | 1.01 | Pelvic lymph nodes + CNS | CR (BM: MRD–; EM: neg) | Pelvic lymph nodes + CNS (CD19+) |
| CD19-LENTI-ALLO001 | M | 11 | TEL/AML1 | Fourth relapse | MFD | CD19-CAR–Lenti_ALLO | 1.0 | 1.92 | BM (0.2) + bone and kidney | CR (BM: MRD–; EM: neg) | Bone |
| CD19-LENTI-ALLO002 | M | 6 | None | Fifth relapse (after 2 HSCTs) | Haplo | CD19-CAR–Lenti_ALLO | 2.0 | 1.49 | BM (83.7) | CR (MRD–) | n.a. |
| CD19-LENTI-ALLO003 | M | 16 | None | Second relapse, very early after HSCT | MFD | CD19-CAR–Lenti_ALLO | 2.0 | 4.17 | BM (0.2) | CR (MRD–) | Pancreas |
| CD19-LENTI-ALLO004 | M | 8 | IKAROS+ | Third relapse, after HSCT | MFD | CD19-CAR–Lenti_ALLO | 3.0 | 7.56 | BM (1.6) | CR (MRD–) | n.a. |
| CD19-LENTI-ALLO005 | M | 7 | t(9;22) | First refractory relapse | MFD | CD19-CAR–Lenti_ALLO | 3.0 (before HSCT) | 4.3 | BM (0.03) | CR (MRD–) | n.a. |
| CD19-LENTI-ALLO006 | M | 17 | None | Second refractory relapse | Haplo | CD19-CAR–Lenti_ALLO | 3.0 | 4.21 | BM (0.01) + bone | CR (BM: MRD–; EM: neg) | n.a. |
| CD19-LENTI-ALLO007 | M | 4 | 47, XY (+21) | First refractory relapse | MFD | CD19-CAR–Lenti_ALLO | 3.0 | 3.15 | BM (0.02) + ocular disease | CR (BM: MRD–; EM: neg) | BM (CD19+) |
| CD19-LENTI-ALLO008 | F | 26 | None | Fourth relapse (after HSCT and autologous CD19-CAR) | Haplo | CD19-CAR–Lenti_ALLO | 3.0 | 1.86 | BM (0.03) + mammary gland + bone | CR (BM: MRD–; EM: neg) | n.a. |
| CD19-LENTI-ALLO009 | M | 9 | None | First refractory relapse | MFD | CD19-CAR–Lenti_ALLO | 3.0 | 5.33 | BM (55) | CR (MRD–) | n.a |
| CD19-LENTI-ALLO010 | F | 33 | KMT2-A | First relapse after HSCT, very early (2 mo) | MFD | CD19-CAR–Lenti_ALLO | 3.0 | 5.33 | BM (35) | CR (MRD–) | n.a. |
| Pt ID . | Sex . | Age (y) . | Cytogenetic anomalies . | Disease phase at infusion . | Donor and HLA matching . | CAR-T product . | CAR+ T cells (×106 cells per kg) . | CAR− T cells (×106 cells per kg) . | Disease status at LD (%) . | Response at d +28 . | Site of relapse . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Allo-CD19 CAR001 | F | 17 | iAmp21 | Second relapse, very early after HSCT | MUD 10/10 | CD19-CAR–Retro_ALLO | 3.0 | 4.24 | BM (0.3) | CR (MRD–) | CNS (CD19–) |
| Allo-CD19 CAR002 | M | 21 | MEF2D/BCL9 | First refractory relapse | MFD | CD19-CAR–Retro_ALLO | 3.0 (before HSCT) | 3.65 | BM (12) + bone (>10 spots) + liver | BM: CR (MRD–); liver: CR; bone: 3 spots | n.a. |
| Allo-CD19 CAR003 | M | 29 | KMT2A | Fifth relapse | MFD | CD19-CAR–Retro_ALLO | 3.0 | 1.01 | Pelvic lymph nodes + CNS | CR (BM: MRD–; EM: neg) | Pelvic lymph nodes + CNS (CD19+) |
| CD19-LENTI-ALLO001 | M | 11 | TEL/AML1 | Fourth relapse | MFD | CD19-CAR–Lenti_ALLO | 1.0 | 1.92 | BM (0.2) + bone and kidney | CR (BM: MRD–; EM: neg) | Bone |
| CD19-LENTI-ALLO002 | M | 6 | None | Fifth relapse (after 2 HSCTs) | Haplo | CD19-CAR–Lenti_ALLO | 2.0 | 1.49 | BM (83.7) | CR (MRD–) | n.a. |
| CD19-LENTI-ALLO003 | M | 16 | None | Second relapse, very early after HSCT | MFD | CD19-CAR–Lenti_ALLO | 2.0 | 4.17 | BM (0.2) | CR (MRD–) | Pancreas |
| CD19-LENTI-ALLO004 | M | 8 | IKAROS+ | Third relapse, after HSCT | MFD | CD19-CAR–Lenti_ALLO | 3.0 | 7.56 | BM (1.6) | CR (MRD–) | n.a. |
| CD19-LENTI-ALLO005 | M | 7 | t(9;22) | First refractory relapse | MFD | CD19-CAR–Lenti_ALLO | 3.0 (before HSCT) | 4.3 | BM (0.03) | CR (MRD–) | n.a. |
| CD19-LENTI-ALLO006 | M | 17 | None | Second refractory relapse | Haplo | CD19-CAR–Lenti_ALLO | 3.0 | 4.21 | BM (0.01) + bone | CR (BM: MRD–; EM: neg) | n.a. |
| CD19-LENTI-ALLO007 | M | 4 | 47, XY (+21) | First refractory relapse | MFD | CD19-CAR–Lenti_ALLO | 3.0 | 3.15 | BM (0.02) + ocular disease | CR (BM: MRD–; EM: neg) | BM (CD19+) |
| CD19-LENTI-ALLO008 | F | 26 | None | Fourth relapse (after HSCT and autologous CD19-CAR) | Haplo | CD19-CAR–Lenti_ALLO | 3.0 | 1.86 | BM (0.03) + mammary gland + bone | CR (BM: MRD–; EM: neg) | n.a. |
| CD19-LENTI-ALLO009 | M | 9 | None | First refractory relapse | MFD | CD19-CAR–Lenti_ALLO | 3.0 | 5.33 | BM (55) | CR (MRD–) | n.a |
| CD19-LENTI-ALLO010 | F | 33 | KMT2-A | First relapse after HSCT, very early (2 mo) | MFD | CD19-CAR–Lenti_ALLO | 3.0 | 5.33 | BM (35) | CR (MRD–) | n.a. |
F, female; FUP, follow-up; Haplo, haploidentical donor; M, male; MUD, matched unrelated donor; n.a. not applicable; pt, patient.